Followers | 80 |
Posts | 3,532 |
Boards Moderated | 0 |
Alias Born | 06/04/2012 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ELGL CHAIRMAN / Merle Ferguson
https://www.marketscreener.com/business-leaders/Merle-Ferguson-06T6V1-E/biography/
Over the next 90-day’s ELGL expects to bring aboard a highly qualified senior management team and advisory board.
New ELGL CEO / John LaViolette
http://www.lawyerdb.org/Lawyer/John-LaViolette/
John S. LaViolette, Partner Attorney
Address: 150 South Rodeo Drive, Third Floor, Beverly Hills, CA 90212
New ELGL President / Sasha Shapiro
https://m.imdb.com/name/nm3782960/
How bout their 100 Global Patents valued at over $3 billion
See filings
GREAT DAY $PRED
Updated $PRED Website with new Products
https://www.predictivebiotech.com/products/
Updated $PRED Website with new Products
https://www.predictivebiotech.com/products/
Predictive Biotech Stem Cells Explained by Clinical Nutritionist Bill Sickert of Da Vinci Medical
Hearing they will be more active on Social Media soon
http://www.Predtechgroup.com
http://www.Predrx.com
http://www.Predictivebiotech.com
http://www.Predictivelabs.com
https://www.linkedin.com/company/predictive-biotech-inc/
https://www.linkedin.com/company/predictive-technology-group-inc/
https://twitter.com/PREDtechgroup
https://www.facebook.com/Predictivebiotech/
E. Robert Wassman, M.D., Chief Medical Officer,
https://www.wplgroup.com/aci/wp-content/uploads/sites/2/4hgrt4y3hdi78t/US-PM1-PrecisionMedicine.pdf
Dr. E. Robert Wassman is Chief Medical Officer at Rosetta Genomics, a leader in the development of microRNA-based diagnostics. He has
been a pioneer in the introduction of genetic testing and personalized medicine for over 30-years with significant contributions to many
innovative and now state-of-the-art laboratory tests. Prior to joining Rosetta Genomics he was Chief Medical and Chief Genomics Officer
at Generation Health where he focused on advancing clinical utility and comparative effectiveness studies for emerging diagnostics,
and analytics of related payer claims. Prior to that he had been focused on the advancing the translation and delivery of cutting-edge
diagnostic technology into clinical service in the areas of rare cell diagnostics and Next Generation DNA sequencing, holding roles as
SVP/Chief Medical Officer of Helicos BioSciences; Co-Founder/CMO of Good Start Genetics, and President/CMO of Celula, Inc.. Prior
to these start-up ventures, he was the Vice President and National Medical Director of Genzyme Genetics where he led new product
evaluation, and was responsible for clinical services and genetic counseling. Early in his career, he was instrumental in the transition of
prenatal diagnosis into the private sector at The Genetics Institute/Alfigen, Inc., where he introduced several novel testing methodologies
to reproductive medicine. As a consultant he aided the clinical introduction of other significant diagnostic advances including Ambry
Genetics, Prometheus Laboratories, Adeeza Biomedical, and Amoco (Vysis). He received his B.S. cum laude from Yale University and
his M.D. from Albany Medical College, where as a Beebe Scholar he studied at the National Institutes of Health. He did a pediatric
residency at Cornell-NY Hospital, including work at Memorial Sloan-Kettering Cancer Center. He subsequently completed a Fellowship
in medical genetics at Harbor-UCLA Medical Center, and later the Executive Program in Managed Care of the Harvard School of Public
Health. Dr. Wassman is board certified in pediatrics, clinical genetics and clinical cytogenetics, and has licensure in molecular
diagnostics
Did news come out on the NASDAQ WEB SITE >>>???
https://www.nasdaq.com/press-release/predictive-laboratories-to-present-new-endometriosis-discoveries-in-three-presentations-at-leading-20190802-00408
exactly on the Gates Team -
but no one is discussing PRED's Dr WARD on the Preeclampsia ORG BOARD as well, speaks volume too !! http://predrx.com/management/
Dr Kenneth WARD
Chairman and CEO at Juneau Biosciences. Board certification in Obstetrics and Gynecology, Maternal Fetal Medicine, Molecular Genetics and Medical Genetics.
His stock price opinion is $5 short term $20 this year based on $PRED doing a deal with the @BillGates Organization @gatesfoundation / Preeclampsia Foundation....
BILL GATES BEHIND Preeclampsia Registry so is Dr Kenneth WARD
https://www.preeclampsiaregistry.org/about-us
yup - that makes sense
AMAZING POST Inzane !!
he states he didn't sell - he MUST HAVE had to disclose if he did
I called to verify personally - why dont you as well and report back honestly
contact at (561) 400-8608 HotStocks.NYC
how so ?
Bird Man Responds to Hindenberg
good one Rain ... Looks like the shorts are running out of steam here
the saving grace here is if they want to cash in they have to buy back
hoping the co has some big BOOMS coming -
hopeful of a violent reversal soon !!
Worth a Re Read .the co's last PR...
No worries
(Short) Storm shall Pass
on Google / Pfizer in talks to merge off-patent assets with Mylan
https://www.google.com/amp/s/amp.ft.com/content/267f06cc-b0aa-11e9-bec9-fdcab53d6959
Pfizer is in the late stages of talks to combine its off-patent assets with Mylan’s $10bn generics business in a stock deal, according to people familiar with the matter.
The deal, likely to be announced on Monday, would create a large seller of off-patent and generic medicines, including former blockbuster brands Lipitor and Viagra. Mylan shareholders will hold just over 40 per cent of the new venture, and Pfizer will sell debt of about $12bn, the people said.
The plans would also see Mylan’s chief executive Heather Bresch depart, after leading the company for seven years.
Shares in Mylan have fallen by three-quarters since their peak in 2015, as the generics maker struggled with declining prices in the US. It also caused controversy by dramatically raising the price of EpiPens, used to treat allergic reactions.
In August 2018, Mylan’s board of directors announced it would undertake a strategic review of its options, because it feared US public markets were undervaluing the company. Last quarter, the company said sales of its multiple sclerosis drug were worse than expected, and it failed to received approval to make a generic version of Advair, an asthma medicine developed by UK pharmaceutical company GlaxoSmithKline.
If the deal goes through, Michael Goettler, who runs Upjohn, Pfizer’s off-patent drugs business based in Shanghai, will become chief executive of the new venture, while Robert Coury, Mylan’s chairman, would become its executive chairman, the people said. The deal was first reported by The Wall Street Journal.
Pfizer has been trying to reposition itself as a smaller company focused on more innovative medicines and vaccines. To this end, it is spinning off its consumer health business into a joint venture with GSK’s consumer business. It is also making acquisitions to bolster its position in advanced areas such as oncology, buying Array BioPharma, a Colorado-based drugmaker, in June for $10.6bn.
Pfizer has also been under political pressure, including from US president Donald Trump, about raising drug prices, including for erectile dysfunction treatment Viagra and other drugs in the Upjohn business.
The deal would be the latest in a series of large pharmaceutical mergers and acquisitions this year. Bristol-Myers Squibb is seeking regulatory approval for its $90bn purchase of biotech Celgene. Last month AbbVie announced its intention to buy Allergan, the maker of Botox, for $63bn.
The unit will focus on drugs where exclusivity has expired. It will combine generic medicines, often made by different companies than the original drug, with off-patent drugs, which Pfizer used to sell as key brands before their patent protection ended.
He the Bird GURU gives his advice only
He shares his thoughts from his history of the co over 3 years and many co contacts (3rd party) and his 50 year trading history
Cant confirm if videos were deleted or not .. doesn't matter either way.. he never disclosed anything inappropriate.. just just opinion or rumors he heard
Nothing wrong with that or his $300 price target based on future REVS with conservative multiples opinion only..nothing wrong with that
If he sold his restricted shares and "never" disclosed he could go to jail (again - from the 1980"s)
For a PnD to work you need 2 components a Pump which there may have been and a Dump of which there never was
He never dumped his restricted shares ... guaranteed
If he did and didnt disclose he could go to jail
. .. so he didnt or he would have disclosed
He learned his lesson and worked with the SEC for 7,8 years in the 1980s 1990s
He is 76 years old
He would NEVER do anything illegal again!!!
His trading shares he doesnt need to disclose
But the co issued restricted shares (175,000) of which his 1st sell order is $21.75
He MUST and WILL disclose .. ask him
MUST MUST MUST
I have been to his house 10 times already and may go this afternoon too
He works "as if" the SEC and FBI are sitting on his desk
His $300 price prediction is still in tact
Maybe delayed a bit with all the drama here
Buy the dips IMO
Pred is real
Amazing world class management inc. Former COO of Pfizer.. (more to come w them IMO)
w real global partners in Thermo Fisher to start and more to come IMO
News Blackout Period Pre Nasdaq per Piper's advice.. rumor
The company's hand are tied ... Barry feels they have had enough abuse on OTC
Hopeful for a serious reversal with impactful news and $ guidance
$2 is a joke IMO
Global partnership w Thermo Fisher for starters
I bot more at the close yest
Lots of silly noise here
LONG and adding
HoD = SHORT COVERING
CNBC on Marijuana in ASIA
Medical cannabis is gaining momentum in Asia
Many countries in Asia have made headlines for strict punishments for cannabis, but some are nevertheless softening their attitude toward the once-taboo drug.
https://www.cnbc.com/2019/07/15/medical-cannabis-is-gaining-momentum-in-asia.html
With Thailand's legalization of medical cannabis in February, some experts predict that other Southeast Asian countries may move to decriminalize the plant.
If that happens, it could prove a significant opportunity for investors interested in the space.
Many countries in Asia have made headlines for strict punishments for possessing, trafficking and consuming cannabis — including, notable, the ongoing bloody war on drugs in the Philippines. But some nations are nevertheless softening their attitude toward the once-taboo drug, and bringing it to hospitals in the region.
Sent from the CNBC App. Available on Google Play - https://play.google.com/store/apps/details?id=com.cnbc.client&referrer=utm_source%3Dgoogle%26utm_medium%3Demail%26anid%3Dadmob
I hear 1 group has over 300k shares to buy tomorrow
For starters
Should be a better wk IMHO
Nice Post StockGuro !
Amazing Post thanks for sharing your personal visit with Pred
Cooler Heads will Prevail
Time to change direction
The U.S. Cord Blood Banking (CBB) services market was valued over USD 17.2 billion in 2016 and is expected to reach over USD 49.09 billion at CAGR of around 12.2% during the forecast period. High awareness regarding benefits of cord blood
https://parentsguidecordblood.org/en/news/cellsure-brings-disruptive-innovation-banking-stem-cells
Excellent Response..
Great Post !!
CEO and CFO should be in JAIL for stating 2018 guidance of $18 million and only did $100k... if that
What is their new forward guidance of more promised millions ,,,, hmmm
never sharing the revised lower guidance as they sold shares and their conversion friends sold their shares
meanwhile hyping their robots all over town with fancy pictures and statements of amazing deals to come - suckering guys like me and my friends in .. today's PR is another example of BS as the PPS reflects
another 1/100 RS and now lower than before meanwhile they are probably selling and converting and laughing all the way down
Embarrassed to say how much I and friends lost following these crooks to the depths of hell
Embarrassed to say how much I believed these guys and trusted them
Best of luck to all
New Stadium for $NNSR / Green Zebra ?
Welcome to Omaha ne cold and snowing @wmcolesmith meetings Monday. Have a great week... pic.twitter.com/QVnJvJm4M2
— GZ6G Technologies (@greenzebra) December 3, 2018
new $NNSR / GreenZebra SHAREHOLDER WebPage
https://greenzebra.net/ship/
Guessing the XBRL Files Link for SEC Filings and Stock Quote will be added
($NNSR) Green Zebra, a subsidiary of NanoSensors, Inc. announces 4th qtr. smartMedia WiFi revenue forecast for smartAirports, smartStadiums and smartCities
https://apnews.com/a572b72dd047fc6ffb80d2028597634f
Green Zebra Media, Corp.
an hour ago
LAS VEGAS, Nevada, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Shareholder Update – Publicly held NanoSensors, Inc. (OTC Pink: NNSR) announces Green Zebra, a subsidiary of NanoSensors Inc. 4th qtr. Revenue expectations. While NanoSensors Inc. has been focusing on getting OTC Pink current completed, the Green Zebra sales & marketing teams have been busy working diligently transitioning Green Zebra’s business projects, client relationships and lenders into the public company structure.
NanoSensors Inc. CEO/President Coleman Smith states: “We are extremely pleased with Green Zebra’s smooth transition from private into a Pink Current public company. Our sales, marketing and strategic partners continued to push forward on smartMedia contracts and agreements. We expect $10-$12 million dollars USD long–term contract sales for 4th Qtr. ending 2018. Green Zebra’s global sales pipeline entering 2019 puts the company on course to have a record-breaking 2019. We are truly at the right place, at the right time to be entering an emerging wireless 5G market place.”
SmartMedia & Wireless Technology ProjectsGreen Zebra “ The Agency” a subsidiary of Nanosensors Inc.
NEW smartAirport projects – Green Zebra has been awarded a long-term government contract to provide smartMedia wifi services and data analytics for two United States airports that serve 50 million travel visitors annually. The airports authorities will publish a public announcement to their website in the near future; we are hopeful to provide a joint press release announcing the opportunity.
Airport Gross revenue contracts range from 5 to 8 million per airport. Additional revenue share services offered include daily user wifi access fees that range from $4.95 to $9.95 per visitor, digital signage and advertising sponsorship services.
New smartStadiums Projects - Green Zebra has been in negotiations with telecom partners and clients to provide multiple Sports stadiums with long-term contracts utilizing Green Zebra’s smartMedia technology, WiFi marketing and sponsor financing solutions. Green Zebra expects to finalize 2 sports stadium agreements in December 2018.
Green Zebra expects annual SmartMedia WiFi revenue per stadium at $1.5 million per year for smartMedia wifi solutions; $20 million minimum per year when venue sponsor-naming rights and digital signage are included in Green Zebra agreements. Venue Contract terms: 5-10 year agreements.
NEW smartCity Projects - Green Zebra has been in negotiations with several SmartCity projects. Announcements expected Dec. 2018 / Jan 2019. Gross revenue ranges 500k to 2.5 million per year per project depending on the venue or location with in the city.
Green Zebra expects to be the exclusive Agency of Record for supplying wireless, digital, wifi marketing technology and sponsorships solutions. Sponsorship revenues are expected to increase year over year as Green Zebra advisors uncover additional IoT technology and sponsorship opportunities with venue executive stakeholders.
Green Zebra’s Traditional Financing and Lending Options
Green Zebra transitioned existing private lenders and banking relationships into the public company, we will continue to work with traditional lenders to support operations as new projects develop.
-- Green Zebra re-established its traditional bank line of credit for $2.4 million. The lender is a single private lender that provides accounts receivable financing at 1.25% per month. 100% of the business line of credit is available for projects as of November 27, 2018. -- Green Zebra also re-established its private lender for client financing. The private lender offers up to 90% financing, low interest to assist clients with wireless technology and managed service purchases. -- Green Zebra provides global and national sponsors financing to provide venues with additional sources of financing for wireless IoT technologies for venue owners.
We will continue to explore traditional banking options to support smartMedia and wireless IoT projects going forward. Green Zebra finds ways to help client’s manage cash flow for necessary technology upgrades.
Next Announcement: International smartMedia & Wireless Project revenues 4th QTR 2018
About Green Zebra Media, Corp, A subsidiary of NanoSensors:
Green Zebra Media, a global innovative leader in smartMedia wireless marketing & data analytics focused on smartTechnology and sponsor solutions for the location-based smartCities, smartStadiums, smartAirports, smartVenues and other Live and Location Based IoT Entertainment experiences.
About NanoSensors, Inc.
(OTC Pink: NNSR) (OTC Pink: NNSR) An innovative industry leader for smartMedia, wireless communications, IoT Software solutions & data analytics for smartCities, hotels, stadiums, airports, outdoor venues and multi-location venues. Wireless, digital & IoT Technology products and services include proprietary and licensed technology solutions.----
Safe Harbor Statement
Safe Harbor Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that would cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company denies any responsibility to update any forward-looking statements.
To be added to our distribution list, please email, customersupport@greenzebra.net. For more information, visit us at www.greenzebra.net, www.twitter.com/greenzebraContact Information cole@greenzebra.net.
SOURCE: Green Zebra Media Corp
$NNSR Status and Next Steps
https://www.otcmarkets.com/stock/NNSR/news/story?e&id=1227040
Finalize Business Acquisitions after Nanosensors FYE 11/30/2018
Finalize acquisition and complete audit – Redstone Chip technology.
Finalize acquisition and complete audit - Green Zebra Media
Note: Coleman Smith 500 million restricted shares expected to be removed from common shares after corporate symbol and OTC name change and FYE audits.
$NNSR / #GREENZEBRA NEWS
"SmartVenue WiFi projects expected to exceed $100 million by 2021 to accelerate GZ growth."
https://ih.advfn.com/p.php?pid=nmona&article=78708931
#WiFi #SmartCities @CNBC @CNNBusiness @BW @FoxBusiness @FoxBusiness @business @ReutersBiz @WSJecon #IoT @CNBCi @cnni $CTL
$NXEN New CEO Audio Interview
Nexien BioPharma, Inc (OTC: $NXEN) Developing a cannabinoid-based drug pipeline.:
http://www.wallstreetreporter.com/2018/11/nexien-biopharma-inc-otc-nxen-developing-a-cannabinoid-based-drug-pipeline/
https://nexienbiopharma.com/